Search Results

Susan G. Komen®, the world’s leading breast cancer organization, announced $10.05 million in research grants that aim to improve patient lives through better treatments for metastatic disease and advancements in precision medicine.

Susan G. Komen®, the world’s leading breast cancer organization, announced four new global leaders to serve on its Board of Directors.

Susan G. Komen®, the world’s leading breast cancer organization and Walgreens announced another milestone in the transformative five-year collaboration that has not only propelled groundbreaking research in breast cancer but has also significantly expanded access to essential breast health and breast cancer services, support and resources.

Susan G. Komen®, the world’s leading breast cancer organization, has launched the Stand for H.E.R. – A Health Equity Revolution Breast Cancer Impact Report.

Susan G. Komen ® , the world’s leading breast cancer organization, today announced the awarding of 49 new grants to researchers at 28 leading institutions in the U.S.

Susan G. Komen®, the world’s leading breast cancer organization, has appointed nine world-renowned medical and research experts to serve as advisors to the organization.

Susan G. Komen®, the world’s leading breast cancer organization, will hold an in-person Race for the Cure to raise critical funds that support breast cancer patients and advance research that brings us closer to the cures.

Susan G. Komen®, the world’s leading breast cancer organization, will hold an in-person MORE THAN PINK Walk to raise critical funds that support breast cancer patients and advance research that brings us closer to the cures.

Susan G. Komen ® , the world’s leading breast cancer organization, will hold an in-person MORE THAN PINK Walk to raise critical funds that support breast cancer patients and health equity programs, including Susan G. Komen’s Stand for H.E.R.

Guardant Health, Inc and Susan G. Komen® announced today that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify early-stage breast cancer patients who are at high risk of disease recurrence and may benefit from additional monitoring or therapy.